Novo Nordisk A/S

NOVO-B.CO · Moat type: REGULIERUNG

MoatScore

10/10

Fair Value

536 DKK (≈ 81.96 USD)

Margin of Safety

+38.3 %

Rating

STARK

GESCHÄFTSMODELL Novo Nordisk develops, manufactures, and distributes prescription pharmaceuticals — particularly patent-protected preparations for diabetes and obesity (GLP-1 class) — and generates revenues primarily through global marketing of these therapeutics with structurally high pricing power versus patients, insurers, and state healthcare systems.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.